Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan.

"supplemental table 6 . the 5-year cif"

"Conflict-of-interest disclosure: The authors declare no competing financial interests."

"This work was supported in part by Japanese Society for the Promotion of Science KAKENHI grant 21K08391 (J.K.) and Japanese Agency for Medical Research and Developement grant 21ek0510034h0001 (J.K.)."

"OS and PFS were evaluated using the Kaplan-Meier method, and lymphoid neoplasm progression/relapse and NRM were calculated based on the cumulative incidence function (CIF) to account for competing risks. The effects of patient and transplant characteristics on the outcomes of interest were assessed using the Cox proportional hazard model for OS and PFS, Fine and Gray proportional subhazards model for progression/relapse, NRM, neutrophil engraftment, and acute and chronic GVHD. The competing events were death without progression/relapse for progression/relapse, death without engraftment for engraftment, progression/relapse for NRM, and death without acute or chronic GVHD for acute and chronic GVHD. Chronic GVHD was assessed for patients who survived for at least 100 days after transplantation. Covariates considered were transplant year (continuous variable), patient sex, patient age (<50 or ≥50 years old), Karnofsky Performance Status (40-80, 90-100), hematopoietic cell transplantation-specific comorbidity index (Japanese cohort only), history of autologous hematopoietic stem cell transplantation (HCT) before CBT, refined disease risk index (rDRI), patients’ cytomegalovirus infection status, total nucleated cell (TNC) counts (quartile in each registry), CD34+ cell counts (quartile in each registry), number of HLA mismatches (<2 or ≥2 locus mismatches out of 6 loci), the combination of intensity of conditioning regimen (RIC or MAC) and the use of total body irradiation (TBI) (TBI-RIC, TBI-MAC, non–TBI-RIC, non–TBI-MAC), use of anti-thymocyte globulin (ATG) as a GVHD prophylaxis (European cohort only), GVHD prophylactic regimen other than ATG. For variables with >5% missing values, the missing data were included as a separate category. Covariates were selected in the preceding multivariate analysis for each registry in a stepwise manner, with a variable retention criterion of P value <.05. All covariates selected from 1 or both registries were included in the corresponding subsequent multivariate analysis. Variables with P values <.05 were considered significant."